In April 2025, the FDA granted Breakthrough Device designation to SeaStar Medical’s Selective Cytopheretic Device (SCD), recognizing its potential to address a critical unmet need in post-cardiac surgery care. The SCD is designed to manage systemic inflammatory response syndrome (SIRS), a potentially life-threatening complication that can occur following major cardiac procedures. This breakthrough status highlights…